Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferiprone for Secondary Degeneration After Stroke
NCT05111821Phase 2Terminated
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jun 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of deferiprone in ischemic stroke (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: R2* Index within the homolateral black substance at 6 Month. Started Jun 2022; status: terminated.
02
Drugs
deferiprone
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05111821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05111821.